CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ImageneBio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ImageneBio Inc
12526 High Bluff Drive, Suite 345
Phone: (857) 273-8343p:857 273-8343 SAN DIEGO, CA  02210  United States Ticker: IMAIMA
Business Summary
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director KristinYarema 54 7/25/2025 7/25/2025
Principal Financial Officer, Company Secretary JotinMarango 46 7/25/2025 4/25/2022
Senior Vice President - Finance, Administration ErinButler 46 7/25/2025 7/25/2025
Chief Medical Officer YufangLu 61 7/25/2025 7/25/2025

Subsidiaries
Business Name Address City State/Province Country
Inmagene Biopharmaceuticals 12526 High Bluff Drive San Diego CA United States
Pionyr Immunotherapeutics Inc. 2 Tower Pl South San Francisco CA United States

Business Names
Business Name
Amplify Medicines, Inc.
Arrys Therapeutics, Inc.
Ikena Oncology Securities Corporation
4 additional Business Names available in full report.

General Information
Number of Employees: 9 (As of 7/1/2025)
Outstanding Shares: 11,181,676 (As of 7/28/2025)
Shareholders: 42
Stock Exchange: NASD
Federal Tax Id: 001835579
Fax Number: (302) 655-5049


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, August 22, 2025